Top Markets
#1 Akedo Akedo +128.53%
#2 TENDIES TENDIES +95.14%
#3 Threshold Network Threshold Network +43.87%
#4 Verus Coin Verus Coin +43.84%
#5 Mubarak Mubarak +28.64%
#6 Bitway Bitway +24.60%
#7 Palladium Network Palladium Network +22.70%
#8 Cash Cat Cash Cat +21.77%
#9 MultiversX MultiversX +18.70%
#10 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
Coin of the day
Akedo Akedo
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Kedudukan dalam Saham #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Harga Saham
$8.16
Disegerakkan terakhir: 2025-06-26
Modal Pasaran
$234.57M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Regulus Therapeutics Inc. (RGLS)

Kategori

Healthcare
Nisbah P/E bagi Regulus Therapeutics Inc. (RGLS)
Nisbah P/E pada September 2026 TTM: -9.95
Menurut laporan kewangan dan harga saham terkini Regulus Therapeutics Inc., nisbah P/E semasa (TTM) ialah -9.95. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak -0.81.
Sejarah nisbah P/E bagi Regulus Therapeutics Inc. dari 2010 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) -9.95 418.29%
2024 -1.92 137.67%
2023 -0.81 9.47%
2022 -0.74 -25.16%
2021 -0.99 -67.15%
2020 -3.00 263.34%
2019 -0.83 396.22%
2018 -0.17 -88.93%
2017 -1.50 3.59%
2016 -1.45 -81.94%
2015 -8.04 -35.55%
2014 -12.48 -18.09%
2013 -15.23 412.52%
2012 -2.97 1,995.98%
2011 -0.14 104.62%
2010 -0.07 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -415.93%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -470.32%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 76.73%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 134.33%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.